Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of TALEN T512 for HPV16
NCT03226470Phase 1Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Mar 2017
- Primary completion
- Feb 2022
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HPV16-E7-T512 in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection, sponsored by Huazhong University of Science and Technology. Primary endpoint: Number of participants with Adverse Events at 6 months. Status: unknown.
02
Drugs
HPV16-E7-T512
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on NCT03226470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226470.